Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 84 of 317 for:    "Pulmonary Fibrosis, Idiopathic"

A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02707640
Recruitment Status : Completed
First Posted : March 14, 2016
Results First Posted : May 20, 2016
Last Update Posted : May 20, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a Phase 2, randomized, double-blind, placebo-controlled safety and tolerability study of N-acetylcysteine or placebo in participants with mild to moderate idiopathic pulmonary fibrosis (IPF) receiving background pirfenidone therapy.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: Matching Placebo Drug: N-acetylcysteine Drug: Pirfenidone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone
Study Start Date : August 2013
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015


Arm Intervention/treatment
Placebo Comparator: Matching Placebo Drug: Matching Placebo
Matching Placebo, oral administration, three times daily for 24 weeks.

Drug: Pirfenidone
Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.

Experimental: N-Acetylcysteine Drug: N-acetylcysteine
N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.

Drug: Pirfenidone
Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.

Pirfenidone
Background therapy
Drug: Pirfenidone
Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.




Primary Outcome Measures :
  1. Percentage of Participants With Dose Reductions [ Time Frame: From baseline up to 24 weeks ]
    Percentage of participants with dose reductions in N-Acetylcysteine and placebo cohorts during the 24-week treatment period.

  2. Percentage of Participants With Early Treatment Discontinuations [ Time Frame: From baseline up to 24 weeks ]
    Percentage of participants with early treatment discontinuations in N-Acetylcysteine and placebo cohorts during the 24-week treatment period.

  3. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Until 28 days from last dose of study treatment (Week 28) ]
    An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.

  4. Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) [ Time Frame: Until 28 days from last dose of study treatment (Week 28) ]
    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life threatening, requires hospitalization or prolongation of hospitalization, or results in disability/incapacity, or congenital anomaly/birth defect.

  5. Percentage of Participants With Treatment-Emergent Adverse Events Resulting in Permanent Discontinuation of Study Treatment [ Time Frame: Until 28 days from last dose of study treatment (Week 28) ]
  6. Percentage of Participants With Treatment-Emergent Deaths of All Causes [ Time Frame: Until 28 days from last dose of study treatment (Week 28) ]
  7. Percentage of Participants With Treatment-Emergent Adverse Events That Led to Dose Reduction or Temporary Discontinuation of Study Treatment [ Time Frame: Until 28 days from last dose of study treatment (Week 28) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical symptoms consistent with IPF of >=3 months' duration (relative to Day 1)
  • Must have been on a dose of pirfenidone not less than 1602 mg/day for at least 8 weeks prior to randomization at Day 1
  • Able to understand the importance of adherence to study treatment and the study protocol and willing to follow all study requirements, including the concomitant medication restrictions, throughout the study
  • Women of childbearing capacity were required to have a negative serum pregnancy test before treatment and must have agreed to maintain highly effective contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study
  • Diagnosis of usual interstitial pneumonia (UIP) or IPF by high-resolution computed tomography (HRCT) and surgical lung biopsy. Previous HRCT scans, typically and if available, one at the point of time of diagnosis and one more recent, made during the last year before study inclusion, will be used and assessed by a central Reading Committee

Exclusion Criteria:

  • Significant clinical worsening of IPF between screening and Day 1 of study, in the opinion of the investigator
  • Unlikely to comply with the requirements of this study, in the opinion of the investigator
  • Patient-reported cigarette smoking within 3 months of screening or unwilling to avoid use of tobacco products throughout the study
  • History of clinically significant environmental exposure known to cause pulmonary fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds
  • Known cause of interstitial lung disease, including but not limited to radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, and cryptogenic organizing pneumonia
  • Clinical diagnosis of any connective tissue disease, including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis
  • Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis (as a diffuse inflammation of connective tissue and or skin)
  • Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 6 months (relative to Day 1). This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma, squamous skin carcinoma)
  • History of severe hepatic impairment or end-stage liver disease
  • History of end-stage renal disease requiring dialysis
  • History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months (relative to Day 1)
  • Any condition that, in the opinion of the investigator, may have been significantly exacerbated by the known side effects associated with the administration of N-acetylcysteine taken as a single medication
  • Suspected intolerance, allergy, or hypersensitivity to pirfenidone or any of its components
  • Known intolerance, allergy, or hypersensitivity to N-acetylcysteine or any of its components

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02707640


  Show 69 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02707640     History of Changes
Other Study ID Numbers: WA29976
2012-000564-14 ( EudraCT Number )
First Posted: March 14, 2016    Key Record Dates
Results First Posted: May 20, 2016
Last Update Posted: May 20, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Idiopathic Pulmonary Fibrosis
Fibrosis
Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial
Acetylcysteine
N-monoacetylcystine
Pirfenidone
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents